H. Liang

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

B. Han, G. Jiang, H. Pan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Identification of differentially expressed miRNAs in individual breast cancer patient and application in personalized medicine

Z. Zhao, W. Zhou, H. Liang, 2016, Oncogenesis.

Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort

C. Abnet, P. Taylor, S. Dawsey, 2009, Gut.

Comparing gemcitabine-based combination chemotherapy with gemcitabine alone in inoperable pancreatic cancer: A meta-analysis

H. Liang, 2005 .

Association of the genetic polymorphisms of NFKB1 with susceptibility to ovarian cancer.

H. Liang, L. Chen, P. Cai, 2015, Genetics and molecular research : GMR.

Progression in immunotherapy for advanced prostate cancer

H. Liang, Jun Chen, Jiao Guo, 2023, Frontiers in Oncology.

The Role of Circulating T Follicular Helper Cells and Regulatory Cells in Non‐Small Cell Lung Cancer Patients

H. Liang, Y. Xu, L. Liu, 2017, Scandinavian journal of immunology.

Prognostic model for risk stratification of de novo metastatic nasopharyngeal carcinoma patients treated with chemotherapy followed by locoregional radiotherapy.

H. Liang, W. Xia, Y. Xiang, 2021, ESMO open.

Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China

H. Liang, Xiaojia Wang, Yongsheng Wang, 2022, Frontiers in Oncology.

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

B. Han, G. Jiang, H. Pan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.